Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613244 | 0.94 | FYN (0.90) | FYNMKNK1 | |
| SCHEMBL1055715 | 0.90 | FYN (0.81) | FYNMKNK1 | |
| SCHEMBL2949134 | 0.89 | FYN (1.00) | FYNMKNK1 | |
| SCHEMBL2945214 | 0.88 | FYN (1.00) | FYNMKNK1 | |
| SCHEMBL20485969 | 0.88 | FYN (1.00) | FYN | |
| SCHEMBL30521931 | 0.88 | FYN (1.00) | FYN | |
| SCHEMBL2943456 | 0.88 | FYN (1.00) | FYNMKNK1 | |
| SCHEMBL2945923 | 0.86 | FYN (0.75) | FYNMKNK1 | |
| SCHEMBL18613459 | 0.86 | FYN (1.00) | FYN | |
| SCHEMBL4690264 | 0.85 | FYN (0.81) | FYNMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2024-02-08 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | disclosed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885MKNK1 163/4885 |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | FYN 666/4885MKNK1 105/4885 |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885MKNK1 163/4885 |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885MKNK1 163/4885 |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885MKNK1 163/4885 |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885MKNK1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.